The strong chimerism data and planned Phase 3 initiation this month de-risk TSC-101's path to pivotal trial. Monitor for first patient enrollment announcement and any KOL event commentary on market opportunity. The 33% historical win rate at T+20 suggests caution on short-term positioning, but the Phase 3 catalyst is a clear medium-term value driver.
Price Chart
Executive Summary
TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with all 5 patients assessed after a second infusion also achieving complete chimerism. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, supporting a bullish catalyst for this clinical-stage biotech.
Key Facts
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- All 5 patients assessed after second infusion achieved complete chimerism
- 93% of patients responded with decreasing recipient chimerism in higher-risk population vs Cohort A and control
- One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT
- Manufacturing success rate ~90% (17/19) with commercial-ready process
- Company on track to enroll first patient in Phase 3 ALLOHA-2 study this month
- Safety profile consistent with Cohort A; adverse events consistent with post-HCT expectations
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 efficacy or safety results
- Competition from other post-transplant relapse prevention therapies
- Company has no approved products and will need additional financing to complete Phase 3
- Small sample size (14 dosed patients) limits statistical reliability of current data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $0.3204 $0.3119 | ▼ −2.65% | ▼ −2.43% | $0.3242 (+1.19%) |
Sep 2, 2026 4w ago | 8-K | $0.3810 $0.3179 | ▲ +16.56% | ▲ +15.60% | $0.3242 (+14.91%) |
Aug 18, 2026 6w ago | 8-K | $0.7500 $0.7774 | ▼ −3.65% | ▼ −4.04% | $0.3242 (+56.77%) |
Aug 12, 2026 7w ago | 8-K | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Aug 12, 2026 7w ago | Press Release | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3242 (+58.06%) |
Jun 22, 2026 14w ago | 8-K | $0.8651 $0.9775 | ▲ +12.99% | ▲ +13.45% | $0.3242 (−62.52%) |
Jun 22, 2026 14w ago | Press Release | $0.8651 $0.9688 | ▲ +11.99% | ▲ +14.06% | $0.3242 (−62.52%) |
May 6, 2026 21w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −9.13% | $0.3242 (−74.06%) |
Apr 2, 2026 26w ago | 8-K | $1.01 $1.05 | ▲ +3.96% | ▲ +0.34% | $0.3242 (−67.90%) |
Mar 4, 2026 30w ago | Press Release | $1.08 $1.15 | ▲ +6.48% | ▲ +7.81% | $0.3242 (−69.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access